Validation of Noninvasive Markers for HCC Risk Stratification in 1389 Patients With Biopsy-proven NAFLD
Hidenori Toyoda,Hideki Fujii,Michihiro Iwaki,Hideki Hayashi,Satoshi Oeda,Hideyuki Hyogo,Miwa Kawanaka,Asahiro Morishita,Kensuke Munekage,Kazuhito Kawata,Sakura Yamamura,Koji Sawada,Tatsuji Maeshiro,Hiroshi Tobita,Yuichi Yoshida,Masafumi Naito,Asuka Araki,Shingo Arakaki,Takumi Kawaguchi,Hidenao Noritake,Masafumi Ono,Tsutomu Masaki,Satoshi Yasuda,Eiichi Tomita,Masato Yoneda,Norifumi Kawada,Akihiro Tokushige,Yoshihiro Kamada,Hirokazu Takahashi,Shinichiro Ueda,Shinichi Aishima,Yoshio Sumida,Atsushi Nakajima,Takeshi Okanoue,Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD)
DOI: https://doi.org/10.1016/j.gastha.2023.07.018
2023-08-02
Abstract:Background and aims: Nonalcoholic fatty liver diseases (NAFLD) and nonalcoholic steatohepatitis (NASH) can cause hepatocellular carcinoma (HCC). We examined histological features and reported noninvasive markers/models for stratifying the risk of HCC development in patients with biopsy-proven NAFLD or NASH. Methods: A total of 1389 patients who had a histological diagnosis of NAFLD or NASH based on liver biopsy and underwent regular surveillance for HCC were included. The ability to predict HCC development was compared between histological features including liver fibrosis and NAFLD activity score, and noninvasive markers/models including aMAP (age, male, albumin-bilirubin, and platelet) score, FIB-4 (Fibrosis-4) index, and ALBI (albumin-bilirubin) score calculated at the time of biopsy. Results: The C index of aMAP score was 0.887, which was consistent with the original report, comparable to FIB-4 index (0.878), and higher than those of ALBI score (0.789), histological liver fibrosis (0.723), and NAFLD activity score (0.589). The hazard ratios for HCC development in the aMAP intermediate and high-risk groups were 21.0 (95% confidence interval [CI], 3.6-402.0) and 110.3 (95% CI, 16.3-2251.4), respectively, in comparison to the aMAP score low-risk group. Those in the FIB-4 index moderate- and high-fibrosis groups were 10.3 (95% CI, 1.7-199.8) and 93.1 (95% CI, 16.3-1773.8), respectively, in comparison to the FIB-4 index mild-fibrosis group. No patients in the aMAP score low-risk group developed HCC during the study period. Conclusion: For stratifying the risk of HCC development in patients with biopsy-proven NAFLD or NASH, both aMAP score and FIB-4 index showed high discriminative ability as noninvasive markers, which were superior histological features.